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Parkinson‘s disease is a progressive neurodegenerative disease with motoric symptoms 
(tremor, rigidity, akinesia, postural disorders), which are connected with the loss of 
dopaminergic neurons in Substantia nigra pars compacta. Oxidative stress has been associated 
with patological processes of PD as an initiator or a member of patological cascades. Morover, 
oxidative stress plays a role in development of several diseases, e.g. cardiovascular disorders. 
Damages caused by oxidative stress are based on reactive oxidative species (ROS). The most 
common and the most toxic compound is hydroxyl radical, which is created by chemical 
reaction with iron as a catalyst (Fenton reaction). Iron chelators act as protectors against 
oxidative harm in tissues. They chelate iron ions, therefore prevent their catalytic activity and 
formation of ROS. This study deals with the determination of cytotoxicity and protective effects 
of clinically used iron chelators (deferoxamine – DFO, deferiprone – L1, deferasirox – 
ICL670A) in PC12 cell line as in vitro model of dopaminergic neurons with PD, using 6-
hydroxydopamine (6DA) as of oxidative stress inducer. 
In this study we used PC12 cell line that was treated for 7 days with nerve growth factor 
(50 ng/l). 72-hour incubations were performed for tests of iron chelators cytotoxicity. 24-hour 
incubations were performed for tests of iron chelators protective effects, using 100 µM 6DA. 
Lactate dehydrogenase assay was used for assessment of cellular viability. 
100 µM ICL670A showed the highest cytotoxicity (74% of dead cells). 1 and 10 µM L1 
showed the lowest cytotoxicity (15 and 17 % of dead cells, respectively). In tests of protective 
effects 100 µM L1 displayed the best efficiency (66,8 % living cells) and DFO was the worst. 
Therefore chelators L1 and ICL670A tend to have the greatest potential for future studies of 
iron chelation therapy. 
